Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.
Genetic engineering concept. Collage with glowing DNA molecule over female hand on blue background | Image Credit: © Prostock-studio
Mirai Bio (Mirai) announced on May 20, 2025 that the company has entered into a strategic collaboration with Thermo Fisher Scientific aimed at advancing the development and manufacturing of nucleic acid therapeutics (1). The agreement brings together Mirai’s technology platform for the design and optimization of genetic medicines with Thermo Fisher’s development and current good manufacturing practice (CGMP) capabilities.
The collaboration will initially focus on leveraging Thermo Fisher’s RNA and advanced formulations facility to support the industrialization of Mirai’s development candidates, according to the release (1). In addition to technical collaboration, the agreement includes a direct investment into Mirai as part of the broader partnership between Thermo Fisher and Flagship Pioneering, Mirai’s founding organization.
·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.
·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.
·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.
“This collaboration is an expansion of our long-standing relationship with Thermo Fisher and a reflection of our shared vision for accelerating the development of enabling technologies to develop first-in-class therapies,” said Justine Levin-Allerhand, PhD, executive partner, origination and corporate development at Flagship, in the release (1). “In this case, the combination of Mirai’s innovation in targeted delivery and cargo design and Thermo Fisher’s deep technical and commercial manufacturing expertise will maximize opportunities for the co-creation of novel medicines and help realize the full potential of both enterprises.”
Mirai offers end-to-end services for partners in the genetic medicine space. The company’s machine intelligence-based platform enables high-throughput design and in vivo testing of targeted delivery systems, facilitating rapid and scalable development processes.
“Thermo Fisher is a trusted industry leader with deep technical expertise and proven developmental and GMP services and commercial manufacturing capabilities,” said Travis Wilson, executive chairman of Mirai and growth partner, Flagship Pioneering, in the release from Mirai (1). “Coupling these with Mirai’s unique delivery and genetic medicine optimization technologies will support accelerated program development and commercialization for our life science partners worldwide. We’re thrilled to enter into this collaboration to further strengthen Mirai’s platform and fully realize our vision of co-creating targeted, potentially curative programmable medicines with end-to-end optimization.”
Vincent Hingot, president, drug substance, pharma services at Thermo Fisher, stated, “Mirai is on a journey to break down the barriers currently limiting the full potential of genetic medicines and offer fully integrated design, delivery, and manufacturing capabilities to innovative partners. We’re excited to combine our life sciences expertise and manufacturing capabilities with Mirai’s machine intelligence-powered platform to help bring the next generation of medicines to patients in need.”
This new collaboration is part of an ongoing effort by both organizations to address key challenges in genetic medicine development and to jointly create integrated solutions that can support the next wave of therapeutic innovation (1).
Thermo Fisher is focused on working sustainably. Adam Goldstein, senior director of R&D Collaborations at Thermo Fisher Scientific, told Pharmaceutical Technology that sustainability-by-design in bioprocess development involves integrating sustainable practices and principles from the very beginning of the development process, which includes considering environmental impacts, resource efficiency, and waste reduction during the design phase, to create processes that are not only efficient but also lower the environmental footprint (2).
Goldstein went on to emphasize the importance of the innovations that result from adopting a sustainability-by-design approach because they can lead to improved product quality and process efficiency. “Driving higher titer in smaller volumes means yielding higher throughput of product in a smaller footprint. The benefits are lower cost of goods in manufacturing while simultaneously delivering the product in a much more sustainable fashion with regards to emissions reductions,” he commented (2).
Read the full article on sustainability in bioprocess development with Goldstein’s commentary.
References
